G. Germanidis Et Al. , "Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone," 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , vol.40, Massachusetts, United States Of America, 2004
Germanidis, G. Et Al. 2004. Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone. 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , (Massachusetts, United States Of America).
Germanidis, G., Marcellin, P., Lau, G., Bonino, F., Farci, P., Hadziyannis, S., ... Jin, R.(2004). Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone . 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America
Germanidis, G Et Al. "Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone," 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 2004
Germanidis, G Et Al. "Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone." 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , Massachusetts, United States Of America, 2004
Germanidis, G. Et Al. (2004) . "Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone." 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , Massachusetts, United States Of America.
@conferencepaper{conferencepaper, author={G Germanidis Et Al. }, title={Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone}, congress name={55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)}, city={Massachusetts}, country={United States Of America}, year={2004}}